Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
J Cell Mol Med. 2013 Nov;17(11):1415-21. doi: 10.1111/jcmm.12109. Epub 2013 Nov 27.
Tumour-associated Macrophages (TAM) present two different polarizations: classical (M1) characterized by immunostimulation activity and tumour suppression; alternative (M2) characterized by tumour promotion and immune suppression. In this retrospective study, we evaluated the correlation between the two forms of TAM with survival time in radically resected gastric cancer patients. A total of 52 chemo- and radio-naive patients were included. Two slides were prepared for each patient and double-stained for CD68/NOS2 (M1) or CD68/CD163 (M2) and five representative high-power fields per slide were evaluated for TAM count. The median value of the two macrophage populations density and the median value of M1/M2 ratio were used as cut-off. Twenty-seven patients with M1 density above-the-median had a significantly higher survival compared to those below the median. Twenty-six patients with M1/M2 ratio above the median showed median OS of 27.2 months compared to 15.5 months of the patients below the median. No association between M2 macrophage density and patient's outcome was found. In multivariate analysis, M1/M2 was a positive independent predictor of survival. The M1 macrophage density and M1/M2 ratio, as confirmed in multivariate analysis, are factors that can help in predicting patients survival time after radical surgery for gastric cancer.
肿瘤相关巨噬细胞(TAM)呈现出两种不同的极化状态:经典(M1)型具有免疫刺激活性和肿瘤抑制作用;替代(M2)型具有促进肿瘤和免疫抑制作用。在这项回顾性研究中,我们评估了两种形式的 TAM 与根治性切除的胃癌患者生存时间之间的相关性。共纳入 52 例未经化疗和放疗的患者。每位患者制备 2 张切片,分别用 CD68/NOS2(M1)或 CD68/CD163(M2)双重染色,每张切片评估 5 个有代表性的高倍视野的 TAM 计数。两种巨噬细胞群体密度的中位数和 M1/M2 比值的中位数用作截止值。M1 密度高于中位数的 27 例患者的生存时间明显高于中位数以下的患者。M1/M2 比值高于中位数的 26 例患者的中位 OS 为 27.2 个月,而中位数以下的患者为 15.5 个月。未发现 M2 巨噬细胞密度与患者预后之间存在关联。多变量分析显示,M1/M2 是生存的独立正预测因子。M1 巨噬细胞密度和 M1/M2 比值在多变量分析中得到证实,是有助于预测根治性手术后胃癌患者生存时间的因素。